These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26020982)

  • 1. [BRAF inhibitor and MEK inhibitor].
    Uhara H
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of BRAF-mutated metastatic melanoma].
    Boyles TB; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.
    Roukos DH; Papaloukas C; Tzaphlidou M
    Future Oncol; 2013 Jan; 9(1):5-8. PubMed ID: 23252557
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targets in melanoma: map kinase pathway.
    Haluska FG; Ibrahim N
    Curr Oncol Rep; 2006 Sep; 8(5):400-5. PubMed ID: 16901402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Melanoma].
    Uhara H
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
    Gutzmer R
    J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
    [No Abstract]   [Full Text] [Related]  

  • 9. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF signaling and targeted therapies in melanoma.
    Dhomen N; Marais R
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):529-45, ix. PubMed ID: 19464601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to BRAF/MEK Inhibition in Melanoma Is Mediated by the Androgen Receptor.
    Cancer Discov; 2022 Aug; 12(8):1835. PubMed ID: 35748587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
    Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
    Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
    Long G
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
    [No Abstract]   [Full Text] [Related]  

  • 14. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis.
    Zhao CY; Chou S; Liu RC; Fernandez-Peñas P
    Pigment Cell Melanoma Res; 2018 Mar; 31(2):341-344. PubMed ID: 29131505
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF in melanoma: current strategies and future directions.
    Salama AK; Flaherty KT
    Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling.
    Adamopoulos C; Ahmed TA; Tucker MR; Ung PMU; Xiao M; Karoulia Z; Amabile A; Wu X; Aaronson SA; Ang C; Rebecca VW; Brown BD; Schlessinger A; Herlyn M; Wang Q; Shaw DE; Poulikakos PI
    Cancer Discov; 2021 Jul; 11(7):1716-1735. PubMed ID: 33568355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerance of BRAF and MEK inhibitors on metastatic melanoma carrying the orphan pV600_K601 delinsE mutation of the BRAF gene.
    Barbé J; Garnier M; Tallet A; Collin C; Leducq S; Routier É; Machet L; Samimi M
    Int J Dermatol; 2021 Jul; 60(7):e283-e284. PubMed ID: 33734441
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of BRAF inhibitor-induced hyperkeratosis.
    Battley JE; Lenihan E; Redmond HP; Murphy M; Power DG
    Acta Oncol; 2013 May; 52(4):874-7. PubMed ID: 22998476
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.